Ironwood Pharmaceuticals, Inc. (IRWD) Rating Lowered to Sell at ValuEngine
ValuEngine lowered shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from a hold rating to a sell rating in a research note issued to investors on Monday morning.
Several other equities analysts have also recently weighed in on the company. Mizuho reissued a buy rating and set a $20.00 price target (down from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. BidaskClub raised Ironwood Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, August 25th. Cowen and Company set a $20.00 price target on Ironwood Pharmaceuticals and gave the company a buy rating in a report on Monday, August 21st. Wells Fargo & Company set a $19.00 price target on Ironwood Pharmaceuticals and gave the company a buy rating in a report on Saturday, July 22nd. Finally, Wood & Company cut Ironwood Pharmaceuticals from an overweight rating to a neutral rating in a report on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. Ironwood Pharmaceuticals has an average rating of Hold and a consensus target price of $18.29.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded up 1.16% during mid-day trading on Monday, reaching $17.41. The company’s stock had a trading volume of 996,889 shares. The company has a 50-day moving average price of $15.65 and a 200-day moving average price of $16.91. The firm’s market cap is $2.60 billion. Ironwood Pharmaceuticals has a 12-month low of $12.48 and a 12-month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.05). The firm had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70.00 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. Ironwood Pharmaceuticals’s quarterly revenue was up 19.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) earnings per share. On average, equities research analysts expect that Ironwood Pharmaceuticals will post ($1.10) earnings per share for the current year.
WARNING: “Ironwood Pharmaceuticals, Inc. (IRWD) Rating Lowered to Sell at ValuEngine” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/ironwood-pharmaceuticals-inc-irwd-rating-lowered-to-sell-at-valuengine/1613510.html.
Several large investors have recently bought and sold shares of IRWD. Strs Ohio increased its stake in shares of Ironwood Pharmaceuticals by 132.1% in the 1st quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 3,700 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth $192,000. Jane Street Group LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $194,000. Karp Capital Management Corp purchased a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth $201,000. Finally, Raymond James Financial Services Advisors Inc. increased its stake in shares of Ironwood Pharmaceuticals by 8.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 898 shares in the last quarter. Hedge funds and other institutional investors own 97.90% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.